LUC00078I2 - Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta - Google Patents

Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta Download PDF

Info

Publication number: LUC00078I2
Authority: LU; Luxembourg
Prior art keywords: treatment; mediterranean fever; familial mediterranean; beta antibodies; beta
Prior art date: 2005-10-26

Application number

LU00078C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-26

Filing date

2018-06-11

Publication date

2018-08-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00078(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-06-11 Application filed by Novartis Ag filed Critical Novartis Ag

2018-08-14 Publication of LUC00078I2 publication Critical patent/LUC00078I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Zoology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)

LU00078C 2005-10-26 2018-06-11 Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta LUC00078I2 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US73043505P	2005-10-26	2005-10-26
US74212505P	2005-12-02	2005-12-02
EP10181100A EP2332577A1 (fr)	2005-10-26	2006-10-24	Nouvelle utilisation de composés IL-1 béta
EP06826560A EP1940465B1 (fr)	2005-10-26	2006-10-24	Nouvelle utilisation d' anticorps anti il-1beta

Publications (1)

Publication Number	Publication Date
LUC00078I2 true LUC00078I2 (fr)	2018-08-14

Family

ID=37806690

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU92326C LU92326I2 (fr)	2005-10-26	2013-12-05	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU00078C LUC00078I2 (fr)	2005-10-26	2018-06-11	Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LU92326C LU92326I2 (fr)	2005-10-26	2013-12-05	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)

Country Status (28)

Country	Link
US (8)	US8105587B2 (fr)
EP (5)	EP1940465B1 (fr)
JP (4)	JP2009513645A (fr)
KR (3)	KR101749388B1 (fr)
CN (2)	CN101291693B (fr)
AU (1)	AU2006306280B2 (fr)
BR (1)	BRPI0617830B8 (fr)
CA (3)	CA2898369C (fr)
CY (4)	CY1113378T1 (fr)
DK (2)	DK2848258T3 (fr)
ES (3)	ES2944067T3 (fr)
HU (2)	HUE036973T2 (fr)
IL (4)	IL190545A (fr)
JO (2)	JO2826B1 (fr)
LT (3)	LT2848258T (fr)
LU (2)	LU92326I2 (fr)
MA (1)	MA29919B1 (fr)
NO (2)	NO345888B1 (fr)
NZ (1)	NZ567222A (fr)
PH (2)	PH12013501287A1 (fr)
PL (2)	PL1940465T3 (fr)
PT (2)	PT1940465E (fr)
RU (2)	RU2468817C2 (fr)
SI (2)	SI2848258T1 (fr)
TN (1)	TNSN08189A1 (fr)
TR (1)	TR201802449T4 (fr)
TW (3)	TWI537003B (fr)
WO (1)	WO2007050607A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007050607A2 (fr)	2005-10-26	2007-05-03	Novartis Ag	Nouvelle utilisation de composes il-1beta
BRPI0812040A2 (pt)	2007-05-29	2014-10-21	Novartis Ag	Indicações para terapia de anti-il-i-beta
AU2012203932B2 (en) *	2007-05-29	2014-04-24	Novartis Ag	New indications for anti-IL-I-beta therapy
JP5607613B2 (ja) *	2008-06-06	2014-10-15	ゾーマ（ユーエス）リミテッドライアビリティカンパニー	関節リウマチの治療のための方法
EP2196476A1 (fr)	2008-12-10	2010-06-16	Novartis Ag	Formulation d'anticorps
JP5913103B2 (ja)	2009-09-14	2016-04-27	ザリージェンツオブザユニバーシティオブコロラド，アボディーコーポレイトＴＨＥＲＥＧＥＮＴＳＯＦＴＨＥＵＮＩＶＥＲＳＩＴＹＯＦＣＯＬＯＲＡＤＯ，ａｂｏｄｙｃｏｒｐｏｒａｔｅ	酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
WO2011047266A1 (fr) *	2009-10-15	2011-04-21	Abbott Laboratories	Protéines de liaison à l'il-1
PH12012502226A1 (en) *	2010-05-14	2013-02-04	Abbvie Inc	Il-1 binding proteins
CA2821976A1 (fr) *	2010-12-21	2012-09-13	Abbvie Inc.	Immunoglobulines a double domaine variable et leurs utilisations
MX362132B (es)	2011-05-10	2019-01-07	Nestec Sa	Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
WO2017153936A1 (fr)	2016-03-10	2017-09-14	Novartis Ag	Arn messager chimiquement modifié
JP2020523560A (ja)	2017-05-31	2020-08-06	プロメテウスバイオサイエンシーズインコーポレイテッド	クローン病患者の粘膜治癒を評価する方法
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (fr)	2017-06-22	2018-12-27	Novartis Ag	Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
CN112584857A (zh) *	2018-05-09	2021-03-30	诺华股份有限公司	卡那吉努单抗的用途
EP3897613A1 (fr)	2018-12-21	2021-10-27	Novartis AG	Utilisation d'anticorps de liaison à il-1bêta
WO2020128637A1 (fr)	2018-12-21	2020-06-25	Novartis Ag	UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
AU2019409139A1 (en)	2018-12-21	2021-06-03	Novartis Ag	Use of IL-1β binding antibodies
US20200369762A1 (en) *	2018-12-21	2020-11-26	Novartis Ag	Use of il-1beta binding antibodies
TWI793503B (zh) *	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
EP4464329A4 (fr) *	2022-01-10	2025-06-11	GI Innovation, Inc.	Composition pharmaceutique pour la prévention ou le traitement des maladies cérébrales dégénératives, contenant un peptide-1 de type glucagon et un antagoniste du récepteur de l'interleukine-1

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US5350683A (en)	1990-06-05	1994-09-27	Immunex Corporation	DNA encoding type II interleukin-1 receptors
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da)	1990-08-29	2005-10-24	Genpharm Int	Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
WO1995001997A1 (fr) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
WO1995016353A1 (fr)	1993-12-14	1995-06-22	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Traitement systemique par genes des affections des tissus conjonctifs
US6258823B1 (en)	1996-07-12	2001-07-10	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
IL144492A0 (en)	1999-02-10	2002-05-23	Interleukin Genetics Inc	Therapeutics and diagnostics based on an il-1b mutation
CN1181048C (zh) *	1999-07-16	2004-12-22	里奥药物制品有限公司	作为IL-1β和TNF-α的抑制剂的氨基二苯酮
EP1212331B1 (fr)	1999-08-24	2004-04-21	Ariad Gene Therapeutics, Inc.	Analogues d'epirapamycine-28
GB0001448D0 (en)	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
WO2001087328A2 (fr)	2000-05-12	2001-11-22	Immunex Corporation	Inhibiteurs d"interleukine 1 dans le traitement de maladies
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
BRPI0115193B1 (pt)	2000-11-07	2016-08-09	Novartis Ag	derivados de indolilmaleimida, processo para preparação dos mesmos, bem como composição farmacêutica que os compreende
JP2004536605A (ja) *	2001-07-26	2004-12-09	イーライ・リリー・アンド・カンパニー	インターロイキン１β抗体
PL374118A1 (en)	2001-08-07	2005-10-03	Immunex Corporation	Interleukin-1 receptors in the treatment of diseases
AU2002365713A1 (en)	2001-12-01	2003-06-17	John Charles Balson	Ac synchronous generator incorporating a braking mechansim
KR200268109Y1 (ko)	2001-12-06	2002-03-15	김정훈	편평형 무정류자 진동모터
EP1496835A4 (fr)	2002-02-01	2006-10-18	Omeros Corp	Compositions et methodes d'inhibition systemique de la degradation du cartilage
PL216224B1 (pl)	2002-02-01	2014-03-31	Ariad Pharmaceuticals	Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
MXPA04007694A (es)	2002-02-11	2004-11-10	Arkion Life Sciences Llc	Factor inhibidor de citosina purificada.
PE20040079A1 (es)	2002-04-03	2004-04-19	Novartis Ag	Derivados de indolilmaleimida
EP1578411A4 (fr)	2002-12-09	2007-05-02	Univ Texas	Procede d'inhibition selective de la janus tyrosine kinase 3 (jak3)
ES2567198T3 (es) *	2003-01-24	2016-04-20	Applied Molecular Evolution, Inc.	Antagonistas de la IL-1 beta humana
GB0303337D0 (en) *	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
AU2004290413A1 (en)	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methods for monitoring IL-18
US20080207613A1 (en)	2004-01-12	2008-08-28	Cytopia Research Pty Ltd	Selective Kinase Inhibitors
US7615212B2 (en) *	2004-02-26	2009-11-10	Baylor Research Institute	Compositions and methods for the systemic treatment of arthritis
US7531570B2 (en)	2004-05-27	2009-05-12	Vertex Pharmaceuticals Incorporated	Treatment of diseases using ICE inhibitors
MXPA06014126A (es) *	2004-06-04	2007-07-18	Regeneron Pharma	Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
EP1883427A4 (fr)	2005-01-20	2010-04-21	Univ Rochester	Compositions et methodes permettant d'etudier et de traiter des maladies et des troubles inflammatoires
WO2006102342A2 (fr)	2005-03-18	2006-09-28	Microbia, Inc.	Production de caroténoïdes dans de la levure ou des champignons oléagineux
SI2314623T1 (sl)	2005-06-21	2012-11-30	Xoma Technology Ltd	IL beta vezavna protitelesa in njihovi fragmenti
WO2007050607A2 (fr)	2005-10-26	2007-05-03	Novartis Ag	Nouvelle utilisation de composes il-1beta

2006
- 2006-10-24 WO PCT/US2006/041479 patent/WO2007050607A2/fr not_active Ceased
- 2006-10-24 CN CN200680039395XA patent/CN101291693B/zh active Active
- 2006-10-24 CN CN2012102904088A patent/CN102861332A/zh active Pending
- 2006-10-24 NZ NZ567222A patent/NZ567222A/en not_active IP Right Cessation
- 2006-10-24 KR KR1020147035512A patent/KR101749388B1/ko active Active
- 2006-10-24 PT PT06826560T patent/PT1940465E/pt unknown
- 2006-10-24 TR TR2018/02449T patent/TR201802449T4/tr unknown
- 2006-10-24 PT PT141915827T patent/PT2848258T/pt unknown
- 2006-10-24 EP EP06826560A patent/EP1940465B1/fr active Active
- 2006-10-24 EP EP14191582.7A patent/EP2848258B1/fr active Active
- 2006-10-24 DK DK14191582.7T patent/DK2848258T3/en active
- 2006-10-24 BR BRPI0617830A patent/BRPI0617830B8/pt active IP Right Grant
- 2006-10-24 HU HUE14191582A patent/HUE036973T2/hu unknown
- 2006-10-24 EP EP17199544.2A patent/EP3332807B1/fr active Active
- 2006-10-24 SI SI200632245T patent/SI2848258T1/en unknown
- 2006-10-24 SI SI200631412T patent/SI1940465T1/sl unknown
- 2006-10-24 EP EP10181100A patent/EP2332577A1/fr not_active Withdrawn
- 2006-10-24 KR KR1020087009981A patent/KR101518064B1/ko active Active
- 2006-10-24 US US12/090,490 patent/US8105587B2/en active Active
- 2006-10-24 LT LTEP14191582.7T patent/LT2848258T/lt unknown
- 2006-10-24 DK DK06826560.2T patent/DK1940465T3/da active
- 2006-10-24 JP JP2008537878A patent/JP2009513645A/ja not_active Withdrawn
- 2006-10-24 PL PL06826560T patent/PL1940465T3/pl unknown
- 2006-10-24 NO NO20200810A patent/NO345888B1/no unknown
- 2006-10-24 CA CA2898369A patent/CA2898369C/fr active Active
- 2006-10-24 CA CA2626214A patent/CA2626214C/fr active Active
- 2006-10-24 ES ES17199544T patent/ES2944067T3/es active Active
- 2006-10-24 ES ES06826560T patent/ES2389110T3/es active Active
- 2006-10-24 EP EP23155348.8A patent/EP4218815A3/fr active Pending
- 2006-10-24 KR KR1020177008682A patent/KR20170038131A/ko not_active Ceased
- 2006-10-24 PL PL14191582T patent/PL2848258T3/pl unknown
- 2006-10-24 CA CA2963828A patent/CA2963828A1/fr not_active Abandoned
- 2006-10-24 ES ES14191582.7T patent/ES2662420T3/es active Active
- 2006-10-24 RU RU2008120625/15A patent/RU2468817C2/ru active
- 2006-10-24 AU AU2006306280A patent/AU2006306280B2/en active Active
- 2006-10-25 TW TW101132057A patent/TWI537003B/zh active
- 2006-10-25 TW TW095139438A patent/TWI388335B/zh active
- 2006-10-25 TW TW105103583A patent/TWI626056B/zh active
- 2006-10-29 JO JO2006387A patent/JO2826B1/en active
2008
- 2008-03-31 IL IL190545A patent/IL190545A/en active IP Right Grant
- 2008-04-23 MA MA30863A patent/MA29919B1/fr unknown
- 2008-04-25 TN TNP2008000189A patent/TNSN08189A1/en unknown
- 2008-05-23 NO NO20082344A patent/NO345140B1/no unknown
2011
- 2011-10-27 US US13/283,165 patent/US8409576B2/en active Active
2012
- 2012-08-06 RU RU2012133522/15A patent/RU2571563C2/ru active
- 2012-09-24 CY CY20121100867T patent/CY1113378T1/el unknown
2013
- 2013-02-26 US US13/777,609 patent/US20130171167A1/en not_active Abandoned
- 2013-03-27 JP JP2013066205A patent/JP6061747B2/ja active Active
- 2013-06-18 PH PH12013501287A patent/PH12013501287A1/en unknown
- 2013-12-05 LU LU92326C patent/LU92326I2/fr unknown
- 2013-12-06 LT LTPA2013026C patent/LTC1940465I2/lt unknown
- 2013-12-13 CY CY2013046C patent/CY2013046I1/el unknown
2014
- 2014-03-16 JO JOP/2014/0120A patent/JOP20140120B1/ar active
2015
- 2015-07-28 US US14/810,556 patent/US9649377B2/en active Active
- 2015-10-02 JP JP2015196708A patent/JP6286403B2/ja active Active
2016
- 2016-05-02 IL IL245387A patent/IL245387B/en active IP Right Grant
2017
- 2017-04-11 US US15/484,459 patent/US20170218063A1/en not_active Abandoned
- 2017-08-04 JP JP2017151327A patent/JP2017206552A/ja active Pending
2018
- 2018-03-12 US US15/918,136 patent/US20180201674A1/en not_active Abandoned
- 2018-03-12 CY CY20181100301T patent/CY1120018T1/el unknown
- 2018-04-26 IL IL258983A patent/IL258983B/en active IP Right Grant
- 2018-06-11 LU LU00078C patent/LUC00078I2/fr unknown
- 2018-06-11 HU HUS1800025C patent/HUS1800025I1/hu unknown
- 2018-06-12 CY CY2018018C patent/CY2018018I2/el unknown
- 2018-06-12 LT LTPA2018506C patent/LTC2848258I2/lt unknown
2020
- 2020-06-19 US US16/906,118 patent/US20210147533A1/en not_active Abandoned
- 2020-06-23 PH PH12020500559A patent/PH12020500559A1/en unknown
- 2020-09-16 IL IL277406A patent/IL277406A/en unknown
2023
- 2023-02-28 US US18/175,849 patent/US20240083997A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SI1940465T1 (sl)	2012-10-30
CA2898369C (fr)	2017-06-20
EP4218815A3 (fr)	2024-03-27
NO345140B1 (no)	2020-10-12
BRPI0617830B1 (pt)	2020-10-20
CY2013046I2 (el)	2015-11-04
KR101518064B1 (ko)	2015-05-06
HK1204767A1 (en)	2015-12-04
LTPA2018506I1 (lt)	2018-06-25
TWI537003B (zh)	2016-06-11
EP3332807A2 (fr)	2018-06-13
CY1113378T1 (el)	2015-11-04
JP2013166757A (ja)	2013-08-29
EP2848258B1 (fr)	2017-12-13
LTC2848258I2 (lt)	2019-08-12
EP2332577A1 (fr)	2011-06-15
HK1121041A1 (en)	2009-04-17
US20210147533A1 (en)	2021-05-20
EP3332807B1 (fr)	2023-02-22
PT1940465E (pt)	2012-10-03
JP2009513645A (ja)	2009-04-02
US20080286266A1 (en)	2008-11-20
CY2018018I1 (el)	2018-12-12
IL190545A0 (en)	2008-11-03
RU2571563C2 (ru)	2015-12-20
LT2848258T (lt)	2018-02-26
EP1940465A2 (fr)	2008-07-09
DK2848258T3 (en)	2018-03-19
TW200803898A (en)	2008-01-16
CY2018018I2 (el)	2018-12-12
BRPI0617830B8 (pt)	2021-05-25
CY1120018T1 (el)	2018-12-12
US20170218063A1 (en)	2017-08-03
HUS1800025I1 (hu)	2018-07-30
CY2013046I1 (el)	2015-11-04
US20130171167A1 (en)	2013-07-04
US8409576B2 (en)	2013-04-02
US20180201674A1 (en)	2018-07-19
PL2848258T3 (pl)	2018-06-29
RU2008120625A (ru)	2010-01-20
JP6061747B2 (ja)	2017-01-18
TWI626056B (zh)	2018-06-11
PH12013501287B1 (en)	2016-02-01
JP2016020377A (ja)	2016-02-04
CA2898369A1 (fr)	2007-05-03
US20150322148A1 (en)	2015-11-12
NO345888B1 (no)	2021-09-27
MA29919B1 (fr)	2008-11-03
TNSN08189A1 (en)	2009-10-30
JP6286403B2 (ja)	2018-02-28
NZ567222A (en)	2011-07-29
TW201617097A (zh)	2016-05-16
JP2017206552A (ja)	2017-11-24
IL190545A (en)	2016-09-29
ES2389110T3 (es)	2012-10-23
CN102861332A (zh)	2013-01-09
EP2848258A1 (fr)	2015-03-18
US8105587B2 (en)	2012-01-31
IL258983A (en)	2018-06-28
AU2006306280B2 (en)	2010-06-17
IL245387B (en)	2019-09-26
NO20082344L (no)	2008-07-22
JOP20140120B1 (ar)	2021-08-17
HUE036973T2 (hu)	2018-08-28
CN101291693B (zh)	2012-10-03
EP3332807A3 (fr)	2018-06-20
PL1940465T3 (pl)	2013-01-31
PT2848258T (pt)	2018-03-20
IL258983B (en)	2020-10-29
CA2626214A1 (fr)	2007-05-03
KR101749388B1 (ko)	2017-06-20
CN101291693A (zh)	2008-10-22
TR201802449T4 (tr)	2018-03-21
TW201302220A (zh)	2013-01-16
EP4218815A2 (fr)	2023-08-02
ES2662420T3 (es)	2018-04-06
CA2626214C (fr)	2016-06-21
US20120039910A1 (en)	2012-02-16
HK1252316A1 (en)	2019-05-24
JO2826B1 (en)	2014-09-15
PH12013501287A1 (en)	2016-02-01
WO2007050607A2 (fr)	2007-05-03
BRPI0617830A2 (pt)	2011-08-09
KR20150013834A (ko)	2015-02-05
WO2007050607A3 (fr)	2007-06-28
US9649377B2 (en)	2017-05-16
TWI388335B (zh)	2013-03-11
LU92326I9 (fr)	2019-01-16
ES2944067T3 (es)	2023-06-19
KR20170038131A (ko)	2017-04-05
US20240083997A1 (en)	2024-03-14
PH12020500559A1 (en)	2021-06-14
RU2468817C2 (ru)	2012-12-10
IL277406A (en)	2020-11-30
IL245387A0 (en)	2016-06-30
LU92326I2 (fr)	2014-02-05
DK1940465T3 (da)	2012-10-22
CA2963828A1 (fr)	2007-05-03
EP1940465B1 (fr)	2012-08-01
NO20200810A1 (no)	2008-07-22
RU2012133522A (ru)	2014-02-20
AU2006306280A1 (en)	2007-05-03
KR20080059598A (ko)	2008-06-30
SI2848258T1 (en)	2018-03-30
LTC1940465I2 (lt)	2017-12-11

Publication	Publication Date	Title
LUC00078I2 (fr)	2018-08-14	Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta
WO2007064972A3 (fr)	2007-11-01	Anticorps monoclonaux et utilisation de ceux-ci
EP2397499A3 (fr)	2013-12-25	Anticorps humains à neutralisation anti-B7RP1
WO2006096489A3 (fr)	2007-03-22	Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits
IL193444A (en)	2015-10-29	Isolated reactive monoclonal antibody that binds both IL-17a and IL-17f, an isolated serum containing it, a diagnostic kit containing it, a pharmaceutical product containing it, and its use as a drug to treat or prevent inflammation or inflammatory disease.
MA31502B1 (fr)	2010-07-01	Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
IL194550A (en)	2015-06-30	Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
CR10099A (es)	2008-09-22	Inmunoglobulinas dirigidas contra nogo
WO2007042261A3 (fr)	2007-12-21	Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
MA29975B1 (fr)	2008-11-03	Antagonistes de la neuropiline
EA201200795A1 (ru)	2013-04-30	Связывающие элементы для пептида с5а с высоким ингибирующим действием
MA30903B1 (fr)	2009-11-02	Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
NO20076663L (no)	2008-02-27	Immunoglobuliner
WO2005070398A8 (fr)	2006-05-04	Compositions pharmaceutiques de candesartan cilexetil stabilisees par des co-solvants
WO2007057748A3 (fr)	2007-09-27	Utilisation du colostrum pour la prophylaxie des syndromes grippaux
WO2008100628A3 (fr)	2008-11-13	Mimétiques de la glutathione peroxydase pour le traitement de maladies neurodégénératives, pulmonaires et inflammatoires
EP2290077A3 (fr)	2011-05-18	Anticorps naturels IgM et leur inhibiteurs
WO2006109045A3 (fr)	2006-12-21	Anticorps et leurs utilisations
HK1053059A1 (zh)	2003-10-10	新用途
HK1152950A (en)	2012-03-16	Treatment of thrombocytopenia
HK1177471A (en)	2013-08-23	Anti-inflammatory antibodies and uses therefor
WO2004087742A3 (fr)	2005-09-01	Peptides et substances mimetiques pour la diminution de symptomes du syndrome de choc toxique et d'un choc septique
HK1142343A (en)	2010-12-03	Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2006128911A3 (fr)	2007-03-29	Utilisation d'isoformes d'il-18bp dans le traitement et/ou la prevention de maladies inflammatoires neurologiques
WO2007009700A3 (fr)	2007-04-05	Utilisation de composes pyrazoliniques substitues pour le traitement de parametres des lipides du syndrome metabolique